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Abstract
The aim of this study was to look at basic endocrinological disorders in chronic kidney disease, acquainting endocrinologists with informa-
tion about the definition and classification of kidney diseases and basic metabolic disorders in uraemia. Secondary hyperparathyroidism, 
insulin resistance and hyperinsulinism, growth hormone disorders and the possibility of growth hormone treatment, the reasons for and 
the consequences of hyperprolactinaemia are presented in a practical way. Thyroid hormones management, a problem which requires 
further study, is portrayed extensively. Hypothalamic–pituitary–adrenal axis disorders are equally complex and not yet fully examined. 
We have largely concentrated on the practical aspects of diagnostics of the presented disorders. (Pol J Endocrinol 2012; 63 (3): 250–257)
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Streszczenie
Autorzy przedstawili podstawowe zaburzenia endokrynologiczne w przewlekłej chorobie nerek, zapoznając endokrynologów z informa-
cjami na temat definicji i klasyfikacji chorób nerek oraz podstawowymi zaburzeniami metabolicznymi w mocznicy. Wtórna nadczynność 
przytarczyc, insulinooporność i hiperinsulinemia, zaburzenia w zakresie hormonu wzrostu, a także możliwości leczenia hormonem 
wzrostu oraz przyczyny i konsekwencje hiperprolaktynemii zostały przedstawione w sposób praktyczny. W szerokim zakresie omówiono 
ponadto hormonalną gospodarkę tarczycową oraz osi podwzgórze–przysadka–nadnercza. Nie wszystkie aspekty są wyjaśnione i wy-
magają dalszych badań. Autorzy w dużej mierze skoncentrowali się na praktycznych aspektach diagnostyki przedstawianych schorzeń. 
(Endokrynol Pol 2012; 63 (3): 250–257)
Słowa kluczowe: niewydolnosć nerek, insulinooporność, hormon wzrostu, hiperprolaktynemia, hormony tarczycy, kortyzol
Introduction
Chronic kidney disease (CKD) has become a great prob-
lem throughout the world. It is connected to increased 
morbidity and mortality and also to decreased quality of 
life in patients compared to the general population [1, 2].
The National Kidney Foundation — Kidney 
Dise ase Outcomes Quality Initiative (NKF-K/DOQI) 
defined CKD as the presence of structural and func-
tional symptoms of renal damage for at least three 
months with or without a glomerular filtration rate 
(GFR) decrease [1].
The classification of CKD depending on GFR value is:
 —  stage 1 — normal GFR (above 90 mL/min/1.73 m2) 
with persistent microalbumin;
 —  stage 2 — GFR 60–89 mL/min/1.73 m2 with persistent 
microalbumin;
 —  stage 3 — GFR 30–59 mL/min/1.73 m2;
 —  stage 4 — GFR 15–29 mL/min/1.73 m2;
 —  stage 5 — GFR below 15 mL/min/1.73 m2 or end-stage 
renal disease (ESRD).
Stages 3–5 are defined as chronic renal failure (CRF).
Diabetes, hypertension, chronic glomerulonephri-
tis, and tubulointerstitial diseases are the commonest 
reasons for CRF. Morbidity and CRF progression rate 
are higher in the USA than in Europe. Scientists link 
this fact with the greater obesity and more frequent 
diabetes and hypertension occurrences in the American 
population [1–3].
Chronic renal failure complications
The gradual deterioration of renal functions initially 
proceeds asymptomatically, but in the further stages 
of CRF, various symptoms and disorders including 
water-electrolyte balance disorders (volume overload, 
hyperkalaemia), metabolic acidosis, hypertension, 
anaemia and hyperphosphataemia with bone disease 
may be observed. Uraemia symptoms include disorders 
of the gastrointestinal tract (lack of appetite, nausea, 
vomiting), circulatory system (pericarditis, muscle over-
growth in left ventricle), nervous system (peripheral 
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neuropathy, concentration disorders, coma, brain death) 
which have no direct connection to the absolute con-
centration of blood urea nitrogen (BUN) or creatinine.
Volume overload is not a significant problem in the 
first stages of CKD, but may be dangerous in the CRF 
period, particularly if a patient does not have residual 
diuresis. This problem is frequently connected to insuf-
ficient sodium removal from the system [4, 5].
Hyperkalaemia develops more frequently in patients 
with oliguria but may be generated by excessive sodium 
consumption in a diet or connected to tissue damage 
or hypoaldosteronism. It is often caused by adhibiting 
medicines from the ACEI and ARB groups or aldoster-
one antagonists [4, 6].
Metabolic acidosis occurs more frequently in the last 
stage of CKD [7, 8]. Acidosis may be one of the impor-
tant reasons for metabolic disorders increase including 
endocrine [4].
One of the greatest problems in CKD is hyper-
phosphataemia connected to a decrease of phosphate 
clearance and insufficient correction of calcium and 
phosphate concentrations by PTH. This disorder is 
considered to be an important reason for cachexia, 
inflammation and the development of vascular 
atherosclerosis conducive to acute cardiovascular 
episodes [9, 10].
Another clinical problem is hypertension, which is 
present in approximately 85% of patients with chronic 
kidney disease. Although hypertension treatment 
(ACEI, ARB, diuretics, beta-blockers) contains the de-
velopment of CKD, it may alter the activity of metabolic 
pathways [11].
More than half of patients in stage 4 of CKD have 
anaemia, many with a haemoglobin level below 
10 g/dL [12]. This is the effect of erythropoiesis disorder 
connected to deficiency of iron and disturbances of 
erythropoiesis excretion in damaged kidneys, recep-
tor resistance to erythropoiesis, and also decrease of 
erythrocyte survival in patients with uraemia. Addi-
tionally, in the course of renal replacement therapy 
with the use of extracorporeal methods, a disintegra-
tion of corpuscles may be observed, which also inten-
sifies anaemia. Anaemia influences a great number 
of symptoms and increases disorders connected to 
chronic kidney disease, particularly an increase of 
complications in cardiovascular diseases, including 
mortality [13]. Currently, treatment for anaemia is 
commenced according to its degree, even in the pre-
dialytic period, and continued in the course of renal 
replacement therapy. In the treatment, erythropoietin 
preparates are employed, but only after balancing 
iron administration. Both anaemia and erythropoietin 
preparates may influence the activity and disorders 
of physiological pathways [14].
Possibilities of chronic renal failure therapy 
(dialysis therapy)
A number of kidney diseases inevitably lead to end 
stage renal failure.
Following a judgement that renal replacement 
therapy will be necessary, renal replacement ther-
apy education should be started with GFR below 
30 mL/min/1.73 m2 and renal replacement therapy itself 
with GFR 10 mL/min. The clinical condition of a patient 
is a decisive factor here. Most patients can be treated 
with haemodialysis or peritoneal dialysis [15]. Various 
factors influence the selection of dialysis type, including 
patient preference, the possibility of ambulatory treat-
ment, and also patient co-operation in peritoneal dialy-
sis treatment. Both methods require several months of 
preparation. Qualification for kidney transplantation 
should be considered for every patient. If possible, this 
is the preferable method. The effectiveness of various 
dialysis therapy methods is similar, although there 
are slight differences in survival rates during the first 
months of treatment in favour of peritoneal dialysis [16].
Endocrinological complications  
in chronic kidney disease
In patients with CKD, numerous extrarenal complica-
tions may be frequently observed. As a result of GFR 
decrease, metabolic disorders occur leading to in-
creased morbidity and death risk, principally because 
of cardiovascular disease. Hormonal disorders also 
occur frequently. The kidneys play a significant part 
in maintaining homeostasis in an organism. They par-
ticipate in the excretion of various hormones: cortisol, 
aldosterone, sex hormones, thyroid gland hormones, 
catecholamine and in biodegradation of peptide hor-
mones such as parathormone, calcitonin and insulin. In 
patients with uraemia, impairment of hormone excre-
tion and biodegradation has been observed, as well as 
disorders affecting excretion, transportation and bind-
ing hormones with target cells, frequently as a result of 
receptor resistance. Renal replacement therapy in the 
advanced stages of renal failure insignificantly influ-
ences the compensation of endocrine disorders [17–19].
PTH and kidneys
All stages of CKD are accompanied by calcium-phos-
phorus balance disorders, and severe secondary hyper-
parathyroidism is a frequent complication in advanced 
CKD and in dialysed patients [20]. Parathormone 
(PTH) is considered to be a uraemic toxin, and its con-
centration in serum increases when GFR drops below 
50–70 mL/min. Prolonged excess of PTH leads to bone 
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mass loss and extraskeletal calcifications, primarily in 
the cardiovascular system [21]. Excessive retention of 
phosphorus due to its decreased ejection by the kidneys 
commences in stage 3 of CKD. In this period, active 
renal parenchyma mass decreases, which leads to a de-
creased production of vitamin D active form (calcitriol; 
1,25-OH D3) and impaired calcium absorption from the 
gastrointestinal tract.
As a result of these abnormalities, decreased con-
centration of ionised calcium and increased excretion 
of PTH occur, and PTH excess leads to the develop-
ment of secondary hyperparathyroidism mobilising 
calcium and phosphorus ions from osseous tissue 
[21, 22]. These disorders are intensified by resistance 
on calcium and vitamin D receptor level as well as 
an excessive number of factors restraining the pro-
duction of active vitamin D [22]. In stage 4 of CKD, 
hypocalcaemia, hyperphosphataemia, decreased 
concentration of vitamin 1,25D and an approximately 
4-fold increase in PTH concentration are common. In 
stage 5 of CKD, PTH concentration increases greatly. 
Therapy in a case of secondary hyperparathyroidism 
is the domain of nephrology [23].
Insulin
In numerous patients with CRF, disorders in carbohy-
drate management are observed. Hyperinsulinaemia 
and insulin resistance occur rather early, although 
glucose concentrations are generally normal. However, 
an increase of HOMA-IR value is reported which is also 
a recognised indicator of insulin resistance in patients 
with CRF [24].
It has been documented that insulin resistance in 
patients with CRF is an independent factor of mortality 
risk due to cardiovascular reasons [25]. Increased insulin 
concentration in CRF is generated by deterioration of 
glomerular filtration and insulin excretion in proximal 
tubules, and also disorders of insulin metabolism in 
proximal tubular cells which leads to a prolonged period 
of insulin half-life. Tubular secretion increases along 
with a drop in GFR, and therefore only at approximate 
15–20 mL/min GFR values decreases significantly 
[26–28].
The molecular mechanisms of insulin resistance are 
not fully understood. It may result from overexpression 
of potential inhibitors in receptor activity of tyrosine 
kinase restraining insulin transfer in a cell PC-1-plasma 
cell membrane glycoprotein-1 [29]. In haemodialysed 
patients, an increased activity of PC-1 in lymphocytes 
has been indicated. It has also been established that 
EPO treatment and anaemia correction connected to 
a decrease of insulin resistance in these patients are 
related to a decrease of PC-1 expression [30].
In consideration of uraemia, secondary hyperpara-
thyroidism and disorders resulting from endocrine 
activity of adipose tissue (hyperleptinaemia) in patients 
with CRF increased insulin excretion by pancreatic islets 
explained as a result of insulin resistance has been ob-
served [31–33]. However, not all scientists confirm the 
increase of insulin excretion in this group of patients. It 
supposedly results from a direct activity of uraemic 
toxins, acidosis and calcitriol deficiency on insulin secre-
tion [26, 34]. It is documented that insulin resistance is 
independent of the stage of renal failure [35]. Gluconeo-
genesis intensification in the liver, a decrease of glucose 
uptake by the liver and skeletal muscles, and disorder 
of intracellular pathways in glucose transformation, 
also lead to impaired glucose metabolism in patients 
with CRF [26]. Insulin resistance may also be a result 
of inflammation in dialysed patients [36].
Prolonged dialysis therapy probably eliminates fac-
tors reducing insulin degradation by extrarenal tissues, 
which improves tissue sensitivity to its impact. The 
study by Tuzcu et al. indicated the improvement of 
insulin resistance only in HD as opposed to CAPD [37]. 
Haemodialysis therapy may accelerate metabolic clear-
ance of insulin [38]. Souza et al. evaluated the influence 
of kidney transplantation on insulin resistance. After 
three months of transplantation, HOMA-IR indicator 
was significantly lower (2.4 ± 1.5 before transplantation 
v. 1.5 ± 1.1 after three months, p < 0.001), but in the fol-
lowing markings it increased. However, it did not reach 
statistical significance (2.0 ± 1.7 — 12 months after trans-
plantation) [39]. This problem requires further studies.
Clinical conclusions
The role of insulin resistance in the development of 
protein energy wasting (PEW) syndrome is not as un-
equivocal as was previously believed. Insulin resistance 
is higher in malnutritioned patients, and is connected 
to inflammation, hyperleptinaemia, calcitriol deficiency 
and acidosis.
It appears that the most important factor for a de-
crease of insulin resistance in patients with CRF is ef-
ficient and productive haemodialysis.
Growth hormone (GH)
In patients with CKD, growth hormone concentra-
tion is generally elevated and increases with disease 
progression, although correct GH excretion may be 
observed following GHRH stimulation [40]. Elevated 
concentration of this hormone is a result of increased 
GH excretion by the pituitary gland, but also by impair-
ments of hormone degradation in the kidneys (GH 
is reabsorbed and metabolised in a proximal tubule) 
[41]. Additionally, the increase of concentration of 
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proteins binding GH is observed which may influence 
its concentration. Paradoxically, in patients with CKD, 
growth hormone excretion intensifies with increased 
glucose concentration, and hypoglycaemia after insu-
lin administration causes only a slight increase of GH 
concentration [42]. GH concentration increases exces-
sively following intravenous administration of arginine. 
Unlike in healthy people, patients with CKD have been 
reported to have increased GH concentration following 
TRH stimulation [43]. Despite elevated GH concentra-
tion in patients with CKD, among children with CKD 
growth disorders may be observed. It seems that this 
results from resistance of peripheral tissues to GH but 
also to IGF-1 and IGF-2. Additionally, activity of IGF-1 
and IGF-2 is decreased by increased binding with IGFPB 
[41, 44, 45]. Therefore, when marking IGF concentra-
tions with the use of biological tests, the results may be 
lowered, and with the use of radioimmunological tests, 
results may be overstated [41]. GH administration in 
children with growth deficiency is a routine treatment 
as it has been proven that GH analogue administration 
enables normal growth in children with CKD [46]. In 
adults, GH analogue administration generates muscle 
mass gain and may be a suitable treatment for protein 
energy wasting (PEW) [47, 48]. However, considering 
the cost of treatment, it cannot be a routine procedure. 
The condition of GH analogue administration is a cor-
rection of acidosis, secondary hyperparathyroidism 
and zinc deficiency [49]. Similar results were acquired 
following GHRH administration [50]. The most frequent 
marginal symptoms of exogenous GH administration 
are oedemas [47, 50].
After commencing dialysis therapy, GH concentra-
tion decreases and HD treatment leads to the increase 
of IGF-1 activity, probably due to elimination of low 
molecular weight inhibitors from circulation [44]. Ad-
ministration of recombined human erythropoietin in 
the course of dialysis also leads to a decrease of basic 
growth hormone concentration [51]. After kidney 
transplantation, normalisation of GH metabolism is 
obtained [46].
Clinical conclusions
The initial GH analogue dose is 0.35 mg/kg/week. The 
most frequent marginal symptoms are oedemas.
GH administration in children with growth defi-
ciency is a routine treatment, and in adults with ESRD 
is tolerable in PEW syndrome treatment.
Prolactin in CKD
PRL concentration in patients with CRF treated with 
HD, PD and during the predialysis period is increased 
in 30–50% of patients, but the clinical consequences of 
this state are not yet fully understood. The concentration 
of this hormone increases along with kidney function 
deterioration, and is highest in patients on renal replace-
ment therapy with the employment of extracorporeal 
circulation. The curve of daily PRL concentration is 
flat, and nightly increase of PRL excretion has not been 
indicated [52]. It is connected with PRL overproduction 
secondarily to a decrease of dopaminergic system activ-
ity and disorder of restraining pituitary PRL excretion. 
However, impairments of stimulation of PRL excretion 
have not been reported, because after TRH stimulation 
a proper increase of PRL concentration is observed [53].
Peripheral mechanisms with the participation of 
hormones such as oestrogens, thyroid hormones, GKK 
and catecholamine also influence prolactin excretion 
[54]. Besides, impaired biodegradation by inefficient 
kidneys leads to hyperprolactinaemia, although some 
authors claim that kidneys are not the only place of PRL 
degradation [55]. It is believed that hyperprolactinae-
mia may be a compensatory mechanism counteracting 
hypocalcaemia as PRL is one of the factors stimulating 
1,25(OH)2D3 synthesis [56]. Hyperprolactinaemia may 
lead to hypogonadism. In order to diagnose hyperpro-
lactinaemia, it is advised that a single PRL measurement 
in blood plasma be performed [57].
The result of a metoclopramide test in patients with 
end-stage renal disease is inadequate, and response 
of PRL excretion is lower. The diagnostic value of 
a metoclopramide test in patients with ESRD is in-
considerable [58].
Neither EPO treatment and haemoglobin level 
increase nor general improvement of health induce 
normalisation of transformed PRL profile, and does 
not normalise the results of a metoclopramide test [52, 
58]. Bromocriptine treatment in patients with CKD 
may be effective in cases of the presence of menstrual 
disorders [57].
Clinical conclusions
A single measurement of PRL concentration above the 
upper limit of normal confirms a diagnosis of hyper-
prolactinaemia. When diagnosing hyperprolactinaemia 
in patients with CKD, a dynamic testing of prolactin 
excretion is not advisable.
Diagnostic imaging may be performed only in cases 
of very high PRL concentration.
Treatment in CRF is rare, only in menstrual disorders 
in young women. 
Influence of kidney disease  
on thyroid hormone functions
In chronic kidney disease, disorders of thyroid func-
tions are observed. Approximately 8% of patients with 
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chronic kidney disease have symptoms of subclinical 
hypothyroidism, and a reduction in the degree of thy-
roid hormone concentrations depends on intensification 
of kidney disease [59, 60].
TSH concentration is normal or elevated but with 
a disturbed rhythm of daily TSH excretion and weak-
ened reaction to TRH. Concentration of fT4 is normal 
or decreased. TT4, TT3, fT3 and rT3 concentrations are 
reduced, unlike in other chronic diseases [61]. In cases 
of reference concentrations of thyroid hormones, rT3 
concentration may yet be increased [61–64].
In haemodialysed patients in uraemia, there is a ten-
dency towards a decrease (but generally still within 
the reference range) of T4 concentration, and low T3 
and rT3 concentrations but without lowering its basic 
concentration compared to patients with kidney disease 
in the predialysis period and dialysed peritoneally. Be-
sides, decreased coefficient values of thyroid hormones 
bindings with proteins (fT4/TT4, fT3/TT3, T4/TBG) and 
elevated concentration of TBG and thyroglobulin have 
been observed [61, 63, 65–67]. It has been indicated that 
increased concentration of uraemic toxins results in 
selective restraint of transcription by receptor blockade 
for T3, which may partially explain disorders of thyroid 
hormones metabolism [68, 69].
Iodum accumulation in an organism along with in-
tensified kidney damage generates an increase of iodum 
quantity stored in the thyroid, which may block produc-
tion of thyroid hormones (Wolff-Chaikoff effect) [70]. It 
is believed that because of this, in patients with CRF one 
may more frequently observe hypothyroidism, thyroid 
nodules, thyroid neoplasm and also goitre which may 
occur increasingly frequently with advancing age. The 
influence of the length of renal replacement therapy on 
occurrences of goitre is not fully understood [65, 71–73].
In advanced CRF stages acidosis persists, which 
may be the reason for decreased fT4 and fT3 concentra-
tions and increased TSH concentration. A significant 
improvement in fT3 concentration in patients cured of 
acidosis has been confirmed which was not indicated 
for fT4, TT4 and TSH. Normalisation of inflammation 
parameters concentration after acidosis compensation 
has not been indicated [61, 74].
Except for disorders of acid-base management, 
disorders of electrolyte management are present in 
chronic kidney disease and elevated phosphate ion 
concentrations may disturb T4 binding with transport 
proteins and increase free thyroxine concentrations [75].
In uraemia, significant changes in transport proteins 
(TBG and albumin) concentration were not indicated, 
although decreased concentrations of these proteins 
may be observed in cachetic patients with present in-
flammation and increased levels of proinflammatory 
cytokines. Besides, accumulated uraemic toxins such 
as urea, creatinine, indoles, and phenols may lead to 
decreased bindings of thyroid hormones and proteins 
(principally prealbumins and albumins) [76].
Some authors have described improvement of thy-
roid functions and decrease of TBG affinity to thyroid 
hormones after haemodialysis [61, 77, 78]. They indicate 
a significant improvement of hormonal state of thyroid 
in patients with ESRD haemodialysed daily [79]. How-
ever, there are other scientists who have not observed 
a positive effect of treatment on disorders of thyroid 
hormones management in dialysis programme [61, 
80]. Following haemodialysis, a decrease of T3 receptor 
restraint by uraemic toxins has been reported which 
reduced organism resistance to the activity of thyroid 
hormones [69].
Even after administration of an insignificant quan-
tity of heparin which is normal for patients dialysed in 
extracorporeal circulation, increased FFA concentration 
is observed which may result in elevation of free thyrox-
ine fraction (fT4) through decreased ability of thyroid 
hormones bindings by TGB [77, 81, 82].
After administration of erythropoietin preparates 
in patients haemodialysed and dialysed peritoneally, 
improvement of T4 and T3 concentrations and TSH 
excretion, including reaction to TRH, has been observed, 
but only a slight influence of this treatment on a daily 
rhythm of hormone excretion has been reported. TSH 
reaction to TRH improves along with an increase of 
haemoglobin (Hb) level [64, 83, 84].
Besides, there has been an indication of a relation-
ship between fT4 and residual kidney function, fT3, 
length of dialysis, concentration of calcium, proteins, 
triglycerides and between TT3 and length of dialysis, 
albumin concentrations and also inverted dependence 
between fT4 and Kt/V [85].
Another important problem is the treatment of 
patients with renal failure and coexisting hyperthyroid-
ism. In the treatment of this group of patients, similar 
procedures are applied but the treatment of l131 re-
quires a significant decrease of dosage in connection 
with a prolonged period of l131 half-life in thyroid [86].
Clinical conclusions
In approximately 30% of patients with CRF, a decrease 
of thyroid hormone concentrations, particularly T3, is 
observed and only approximately 8% are characterised 
by subclinical hypothyroidism. An increase in rT3 con-
centration is not indicated as opposed to other chronic 
diseases.
A diagnosis of a thyreological state in patients with 
CRF requires a complex estimation. Renal replacement 
therapy insignificantly improves a thyreological state in 
patients with ESRD. The substitution treatment of hor-
monal disorders connected to uraemia is not advised.
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The treatment of hyperthyroidism in dialysed pa-
tients with ESRD may be performed with reduced doses 
of l131 in specialised facilities. The dialysis therapy fol-
lowing l131 administration requires special precautions. 
Disorders of the hypothalamic–pituitary– 
–adrenal axis functions in CKD
Evaluating ACTH and cortisol concentrations in patients 
with CKD is complex. However, ACTH and cortisol 
concentrations in serum in this group of patients are 
believed to be normal or insignificantly increased, al-
though the daily rhythm of cortisol excretion remains 
unchanged [87].
In healthy people, the kidneys take part in remov-
ing cortisol and its metabolites soluble in water, and are 
an important site for active cortisol conversion to inac-
tive cortisone with a participation of 11b-hydroxysteroid 
dehydrogenase type 2 (11-bHSD2) which prevents ex-
cessive activation of mineralocorticosteroid receptor by 
cortisol, thus protecting against sodium retention and 
the development of hypertension [88–90]. In CRF, the 
activity of this dehydrogenase is reduced which leads to 
an extended period of cortisol half-life and accumulation 
of its metabolites which may disturb measurements of 
cortisol concentration [87, 91].
Free cortisol level in plasma is increased in a higher 
degree than total, which suggests decreased cortisol 
bindings with albumins, although binding with trans-
cortin (corticol binding globulin) remains unchanged 
[92]. Hypercortisolaemia may be the reason for os-
teopenia, disturbed distribution of adipose tissue, and 
increase of protein catabolism due to elevation of GKS 
concentration [93–95].
It has been indicated that interventions in renal 
replacement therapy (HD) do not significantly improve 
disorders of the hypothalamic–pituitary–adrenal axis; 
however, in dialysed patients, decreased intensifica-
tion of hypercortisolaemia and ACTH concentration 
in comparison with CKD patients on conservative 
management and also normalisation of the cortisol 
half-life period has been observed [95–97]. It has been 
reported that despite a decrease of CRH concentration, 
ACTH and cortisol concentrations increased during HD 
[97]. Besides, it has been observed that elevated cortisol 
concentration was frequently an indication of increased 
morbidity and cachexia, and could be connected to 
a necessity for hospitalisation [88].
Tests of adrenal gland stimulation (ACTH, CRH, 
metyrapone) are generally normal; cortisol concen-
tration increases after ACTH and CRH stimulation, 
although the response to ACTH excretion after CRH 
stimulation is, just like in a chronic stress situation, 
generally suppressed [95, 96]. Improvement of reac-
tion to CRH following EPO administration is indi-
cated as well [93, 94].
The test of adrenal restraint with dexamethasone 
does not produce unequivocal results, something 
which is explained by disturbances in absorption and/or 
slower metabolism [95, 96]. However, in the diagnostics 
of hypercortisolaemia, it is advised to employ a 1 mg 
dexamethasone test since marking a concentration of 
free cortisol in the urine of patients with renal failure 
is non-diagnostic [98].
Clinical conclusions
In patients with CKD, it is possible to observe an incon-
siderable increase of ACTH and cortisol concentrations.
The results of stimulation tests in patients with CKD 
do not alter, and in the diagnostics of hypercortisolaemia 
a 1mg dexamethasone test is advised.
Dialysis therapy does not significantly influence the 
hypothalamic–pituitary–adrenal axis.
Conclusion
The kidneys play an important role in hormonal 
management. Endocrine disorders are one of the 
most crucial elements of ‘uraemic syndrome’ which 
is underestimated and has not been fully examined. 
Pathogenetic relationships are very complex and not 
always obvious. Knowledge of the subject of hormonal 
disorders and their mechanisms in ‘uraemic syndrome’ 
is not widespread among endocrinology doctors.
In the treatment of disorders, the most important 
seem to be the treatment of malnutrition, improve-
ment of the general health state, optimisation of renal 
replacement therapy, and only in exceptional cases 
hormone substitution. Diagnosis, due to the complex-
ity of disorders and the dependency of employed test 
results on their type, is difficult.
In CRF, apart from the discussed disorders, there are 
also complex disorders in the section connected with 
the hypothalamus and pituitary functions, and also 
as far as sex hormones and adipose tissue hormones 
management is concerned. A study of this type is cur-
rently being prepared by the authors.
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